World Health Organisation on Friday announced first six countries that will receive the technology needed to produce mRNA vaccines on the African continent. Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia all applied and have been selected as recipients.
The news: WHO made the announcement at the European Union – African Union summit in Brussels.
- The announcement was made in a ceremony hosted by the European Council, France, South Africa and WHO in the presence of President Macron; President Ramaphosa; President of the European Council, Charles Michel and President of the European Commission, Ursula von der Leyen.
- The global mRNA technology transfer hub was established in 2021 to support manufacturers in low- and middle-income countries to produce their own vaccines, ensuring that they have all the necessary operating procedures and know-how to manufacture mRNA vaccines at scale and according to international standards.
- Primarily set up to address the COVID-19 emergency, the hub has the potential to expand manufacturing capacity for other products as well, putting countries in the driver’s seat when it comes to the kinds of vaccines and other products they need to address their health priorities.
- WHO Director-General, Dr Tedros Adhanom Ghebreyesus said, “No other event like the COVID-19 pandemic has shown that reliance on a few companies to supply global public goods is limiting, and dangerous. In the mid- to long-term, the best way to address health emergencies and reach universal health coverage is to significantly increase the capacity of all regions to manufacture the health products they need, with equitable access as their primary endpoint.”
What’s going on: To ensure that all countries build the necessary capacity to produce their own vaccines and other health technologies, WHO has been working to establish a biomanufacturing workforce training hub that will train people from all interested countries in scientific and clinical research and production capacity.
- The initial effort is centred on mRNA technologies and biologicals, which are important for vaccine manufacturing and can also be used for other products, such as insulin to treat diabetes, cancer medicines and, potentially, vaccines for other priority diseases such as malaria, tuberculosis and HIV. The ultimate goal is to extend capacity building for national and regional production to all health technologies.
- WHO’s current regulatory strengthening activities in low-and middle-income countries will expand through a global benchmarking tool that assesses countries’ ability to ensure the quality, safety and efficacy of health products and provides training where improvements are needed to build regulatory authorities that are agile and fit-for-purpose for the future.